Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction.

The transcription factor Myb plays a key role in the hematopoietic system and has been implicated in the development of leukemia and other human cancers. Inhibition of Myb is therefore emerging as a potential therapeutic strategy for these diseases. However, because of a lack of suitable inhibitors, the feasibility of therapeutic approaches based on Myb inhibition has not been explored. We have identified the triterpenoid Celastrol as a potent low-molecular-weight inhibitor of the interaction of Myb with its cooperation partner p300. We demonstrate that Celastrol suppresses the proliferative potential of acute myeloid leukemia (AML) cells while not affecting normal hematopoietic progenitor cells. Furthermore, Celastrol prolongs the survival of mice in a model of an aggressive AML. Overall, our work demonstrates the therapeutic potential of a small molecule inhibitor of the Myb/p300 interaction for the treatment of AML and provides a starting point for the further development of Myb-inhibitory compounds for the treatment of leukemia and, possibly, other tumors driven by deregulated Myb.

[1]  E. Dmitrovsky,et al.  The Myb–p300 Interaction Is a Novel Molecular Pharmacologic Target , 2015, Molecular Cancer Therapeutics.

[2]  K. Klempnauer,et al.  Naphthol AS-E Phosphate Inhibits the Activity of the Transcription Factor Myb by Blocking the Interaction with the KIX Domain of the Coactivator p300 , 2015, Molecular Cancer Therapeutics.

[3]  Diwakar,et al.  SUPPLEMENTARY INFORMATION for Interaction of c-Myb with p300 is required for the induction of acute myeloid leukemia (AML) by human AML oncogenes , 2014 .

[4]  P. Ye,et al.  MYB down-regulation enhances sensitivity of U937 myeloid leukemia cells to the histone deacetylase inhibitor LBH589 in vitro and in vivo. , 2014, Cancer letters.

[5]  K. Boyd,et al.  Genetic Interaction between Mutations in c-Myb and the KIX Domains of CBP and p300 Affects Multiple Blood Cell Lineages and Influences Both Gene Activation and Repression , 2013, PloS one.

[6]  K. Klempnauer,et al.  Natural sesquiterpene lactones as inhibitors of Myb-dependent gene expression: structure-activity relationships. , 2013, European journal of medicinal chemistry.

[7]  Heather L. Mulder,et al.  Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas , 2013, Nature Genetics.

[8]  D. Pattabiraman,et al.  Role and potential for therapeutic targeting of MYB in leukemia , 2013, Leukemia.

[9]  B. Calabretta,et al.  Expression of p89c-Mybex9b, an alternatively spliced form of c-Myb, is required for proliferation and survival of p210BCR/ABL-expressing cells , 2012, Blood Cancer Journal.

[10]  K. Klempnauer,et al.  Inhibition of Myb-dependent gene expression by the sesquiterpene lactone mexicanin-I , 2012, Leukemia.

[11]  A. Hero,et al.  Identification and characterization of Hoxa9 binding sites in hematopoietic cells. , 2012, Blood.

[12]  B. Calabretta,et al.  c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cells , 2011, Leukemia.

[13]  M. Odero,et al.  In vivo expression of an aberrant MYB-GATA1 fusion induces leukemia in the presence of GATA1 reduced levels , 2011, Leukemia.

[14]  T. Graeber,et al.  An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. , 2011, Genes & development.

[15]  Guang-Biao Zhou,et al.  The Main Anticancer Bullets of the Chinese Medicinal Herb, Thunder God Vine , 2011, Molecules.

[16]  P. Brousset,et al.  Identification of a transforming MYB-GATA1 fusion gene in acute basophilic leukemia: a new entity in male infants. , 2011, Blood.

[17]  S. Koschmieder,et al.  AML1/ETO induces self-renewal in hematopoietic progenitor cells via the Groucho-related amino-terminal AES protein. , 2011, Blood.

[18]  G. Sethi,et al.  Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer. , 2011, Cancer letters.

[19]  A. Salminen,et al.  Celastrol: Molecular targets of Thunder God Vine. , 2010, Biochemical and biophysical research communications.

[20]  C. Bach,et al.  Leukemogenic transformation by HOXA cluster genes. , 2010, Blood.

[21]  Qing Wu,et al.  Effects of Celastrol on growth inhibition of U937 leukemia cells through the regulation of the Notch1/NF-kappaB signaling pathway in vitro. , 2010, Chinese journal of cancer.

[22]  A. Gewirtz,et al.  c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis. , 2010, The Journal of clinical investigation.

[23]  G. Uzan,et al.  HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way , 2010, Molecular Cancer.

[24]  H. Horlings,et al.  Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck , 2009, Proceedings of the National Academy of Sciences.

[25]  D. Pattabiraman,et al.  Mutations in Multiple Domains of c-Myb Disrupt Interaction with CBP/p300 and Abrogate Myeloid Transforming Ability , 2009, Molecular Cancer Research.

[26]  Howard Y. Chang,et al.  Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. , 2009, Cell stem cell.

[27]  F. Bertucci,et al.  Genome profiling of acute myelomonocytic leukemia: alteration of the MYB locus in MYST3-linked cases , 2009, Leukemia.

[28]  B. Calabretta,et al.  Transcriptional repression of c-Myb and GATA-2 is involved in the biologic effects of C/EBPalpha in p210BCR/ABL-expressing cells. , 2008, Blood.

[29]  Robert G. Ramsay,et al.  MYB function in normal and cancer cells , 2008, Nature Reviews Cancer.

[30]  Monica L Guzman,et al.  Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. , 2008, Blood.

[31]  Yulun Huang,et al.  Celastrol inhibits the growth of human glioma xenografts in nude mice through suppressing VEGFR expression. , 2008, Cancer letters.

[32]  B. Calabretta,et al.  Requirement of c-Myb for p210(BCR/ABL)-dependent transformation of hematopoietic progenitors and leukemogenesis. , 2008, Blood.

[33]  Charles Lee,et al.  Alu elements mediate MYB gene tandem duplication in human T-ALL , 2007, The Journal of experimental medicine.

[34]  Thomas F. Meyer,et al.  The Autodisplay Story, from Discovery to Biotechnical and Biomedical Applications , 2007, Microbiology and Molecular Biology Reviews.

[35]  B. Lüscher,et al.  Revisiting a selection of target genes for the hematopoietic transcription factor c-Myb using chromatin immunoprecipitation and c-Myb knockdown. , 2007, Blood cells, molecules & diseases.

[36]  Simon C Barry,et al.  Mechanism of and requirement for estrogen-regulated MYB expression in estrogen-receptor-positive breast cancer cells , 2007, Proceedings of the National Academy of Sciences.

[37]  B. Nadel,et al.  The C-MYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children. , 2007, Blood.

[38]  Rob Pieters,et al.  Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia , 2007, Nature Genetics.

[39]  H. Clevers,et al.  c-Myb is required for progenitor cell homeostasis in colonic crypts , 2007, Proceedings of the National Academy of Sciences.

[40]  G. Zupi,et al.  Mutations in the MYB intron I regulatory sequence increase transcription in colon cancers , 2006, Genes, chromosomes & cancer.

[41]  M. Cleary,et al.  Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. , 2006, Cancer cell.

[42]  Di Chen,et al.  Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. , 2006, Cancer research.

[43]  Joachim Jose,et al.  Autodisplay: efficient bacterial surface display of recombinant proteins , 2006, Applied Microbiology and Biotechnology.

[44]  J. Hess,et al.  c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells. , 2005, Blood.

[45]  M. Tomasson,et al.  c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations. , 2005, Blood.

[46]  K. Rajewsky,et al.  c-Myb is critical for B cell development and maintenance of follicular B cells. , 2005, Immunity.

[47]  L. Tarantino,et al.  c-Myb and p300 regulate hematopoietic stem cell proliferation and differentiation. , 2005, Developmental cell.

[48]  K. Klempnauer,et al.  v-Myb Mediates Cooperation of a Cell-Specific Enhancer with the mim-1 Promoter , 2005, Molecular and Cellular Biology.

[49]  K. Rajewsky,et al.  Critical functions for c-Myb at three checkpoints during thymocyte development , 2004, Nature Immunology.

[50]  W. Alexander,et al.  Suppressor screen in Mpl-/- mice: c-Myb mutation causes supraphysiological production of platelets in the absence of thrombopoietin signaling. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Peter E Wright,et al.  Solution structure of the KIX domain of CBP bound to the transactivation domain of c-Myb. , 2004, Journal of molecular biology.

[52]  G. Anderson,et al.  Progression through key stages of haemopoiesis is dependent on distinct threshold levels of c‐Myb , 2003, The EMBO journal.

[53]  K. Lumb,et al.  Structurally distinct modes of recognition of the KIX domain of CBP by Jun and CREB. , 2002, Biochemistry.

[54]  J. Rehg,et al.  A transcription-factor-binding surface of coactivator p300 is required for haematopoiesis , 2002, Nature.

[55]  I. D'Agnano,et al.  c-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer: clinical and experimental findings. , 2001, The American journal of pathology.

[56]  J. Lipsick,et al.  Transformation by v-Myb , 1999, Oncogene.

[57]  B. Calabretta,et al.  Myb and ets proteins are candidate regulators of c-kit expression in human hematopoietic cells. , 1998, Blood.

[58]  Peter E Wright,et al.  Solution Structure of the KIX Domain of CBP Bound to the Transactivation Domain of CREB: A Model for Activator:Coactivator Interactions , 1997, Cell.

[59]  R. Evans,et al.  Phosphorylation of CREB at Ser-133 induces complex formation with CREB-binding protein via a direct mechanism , 1996, Molecular and cellular biology.

[60]  K. Klempnauer,et al.  Expression of mouse c-myb during embryonic development. , 1995, Oncogene.

[61]  B. Calabretta,et al.  c-myb transactivates cdc2 expression via Myb binding sites in the 5'-flanking region of the human cdc2 gene. , 1993, The Journal of biological chemistry.

[62]  S. Ishii,et al.  Transformation by carboxyl-deleted Myb reflects increased transactivating capacity and disruption of a negative regulatory domain. , 1991, Oncogene.

[63]  S. Swerdlow,et al.  A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis , 1991, Cell.

[64]  B. Calabretta,et al.  Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[65]  N Andrieu,et al.  Strong association between c-myb and oestrogen-receptor expression in human breast cancer. , 1990, Oncogene.

[66]  B. Calabretta,et al.  An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[67]  C. Dani,et al.  Extreme instability of myc mRNA in normal and transformed human cells. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[68]  J. Bishop,et al.  Nucleotide sequence of the retroviral leukemia gene v-myb and its cellular progenitor c-myb: The architecture of a transduced oncogene , 1982, Cell.

[69]  J. Bishop,et al.  The genome and the intracellular RNAs of avian myeloblastosis virus , 1981, Cell.